Pramlintide
⚠️ Disclaimer: For Research Use Only. Not for human administration or clinical therapy. Brand name: Symlin®
Basic Information
- CAS No.: 179246-63-2
- Amino acid sequence: Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu-Val-His-Ser-Ser-Asn-Asn-Phe-Gly-Pro-Ile-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Tyr-NH₂ (Disulfide bond between Cys2 and Cys7; 37 amino acid peptide, amylin analog)
- Molecular Formula: \(\boldsymbol{C_{171}H_{267}N_{51}O_{53}S_{2}}\)
- Molecular Weight: 3949.44 g/mol
- Appearance: White to off-white lyophilized powder
- Solubility: Soluble in weak acidic aqueous buffer
- Storage: Lyophilized powder stored at -20℃, protected from light and moisture. Avoid repeated freeze-thaw cycles. After reconstitution, refrigerate and use promptly.
Development Background
Pramlintide is a synthetic analog of human amylin (islet amyloid polypeptide, IAPP). Native human amylin has high tendency to form amyloid fibrils. Several amino acid substitutions (Pro substitutions) were introduced to reduce aggregation, improve solubility and stability. Marketed as Symlin, used clinically alongside insulin for diabetes management. It is co-secreted with insulin by pancreatic β-cells in healthy people.
Mechanism of Action (Research Findings)
- Agonist of amylin receptors (CTR / CALCR + RAMP heterodimer receptors)
- Slows gastric emptying, suppresses rapid post-meal glucose rise
- Inhibits glucagon secretion in a glucose-dependent manner
- Reduces food intake via hypothalamic appetite suppression
- Modulates satiety signaling
- Proline mutations greatly reduce amyloid fibril formation compared to wild-type human amylin
Research Areas
- Amylin receptor pharmacology
- Diabetes research (type1 / type2, combined insulin therapy models)
- Postprandial glucose regulation
- Appetite & satiety, food intake studies
- Amylin amyloid aggregation & islet amyloid pathology
- Pancreatic islet hormone signaling








评价
目前还没有评价